
Topic
Prior Authorization
Documentation, step edits, renewal cycles, appeals, and how payer criteria shape real-world drug use.

Approvals· August 29, 2026 · 15 min read
By Ran Chen#FDA Approval#JAK Inhibitor#Dermatology

Approvals· August 29, 2026 · 24 min read
Mimrylo for PV Erythrocytosis: 76.9% Week 20-32 Response and Platelet Rises
By Ran Chen#FDA Approval#Hematology#Coverage Access

Approvals· August 29, 2026 · 17 min read
Rasonque's Pancreatic Label Needs No RAS Test: 2L Data Does Not Write 1L Access
By Ran Chen#FDA Approval#Oncology#Coverage Access

Approvals· August 27, 2026 · 20 min read
Imaavy's wAIHA Approval Is a Steroid-Gated, q4w Indication: J9256 Does Not Auto-Cover It

Approvals· August 27, 2026 · 18 min read
Tivicay PD's Neonatal Expansion: Term, 2 kg Floor; Tablets Do Not Substitute
By Ran Chen#FDA Approval#HIV#Infectious Disease

Approvals· August 21, 2026 · 19 min read
Pasatru's FOP Approval: What Garetosmab's $1.4M Launch Means vs Sohonos
By Ran Chen#FDA Approval#BLA Approval#Rare Disease

Pipeline· August 19, 2026 · 20 min read
Avexitide LUCIDITY Phase 3: What the First GLP-1 Antagonist Means for PBH Access
By Ran Chen#Pipeline#GLP-1#Clinical Evidence

Pricing & Access· August 17, 2026 · 25 min read
Tavneos on Formularies as FDA Moves to Withdraw: The Coverage Dilemma

Pricing & Access· August 16, 2026 · 18 min read
Hepatitis C Treatment Access in 2026: Generic Economics, PA, and Sobriety

Pricing & Access· August 13, 2026 · 20 min read
Epilepsy Treatment Access (2026): From $0.02 Generics to Zorevunersen
By Ran Chen#Antiepileptic Drugs#Antisense#Rare Disease